Skip to content

Online Personalized Intervention for the Prevention of Anxiety.

Effectiveness of an Online Personalized Intervention Based on a Risk Algorithm for the Universal Prevention of Anxiety: Randomized Controlled Trial. The prevANS Study.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05682365
Acronym
prevANS
Enrollment
2000
Registered
2023-01-12
Start date
2023-01-30
Completion date
2024-08-31
Last updated
2023-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety Disorders

Keywords

Anxiety Disorders, Primary prevention, Randomized controlled trial, m-Health, e-Health

Brief summary

Objective: To design, develop and evaluate an online personalized intervention based on a risk algorithm for the universal prevention of anxiety disorders in the general population. Methods: Randomized controlled trial, with two parallel arms and 12 months follow-up. The entire process of recruitment, randomization, intervention and follow-up will be carried out from a web platform designed for the study (web prevANS). Through a communication campaign, where announcements and informative videos will be produced, and through the dissemination on prevANS website, 2,000 Spanish and Portuguese adult participants without anxiety in the baseline of the study will be recruited. The participants will be randomly assigned to the prevANS intervention, which will be self-guided and can be implemented from the prevANS web or from the participants' Smartphone (through an APP), or to a control group. The prevANS intervention will have different intensities depending on the risk level of the population, evaluated from the already validated risk algorithm for anxiety: predictA. Participants with a low risk of anxiety will receive information on their level and profile (risk factors) of anxiety and psychoeducational information periodically. Participants with moderate and high risk of anxiety will also receive information on their risk level and profile, but will also include a cognitive-behavioral training (problem solving, decision-making, handling thoughts / concerns and emotions and communicational skills). Both groups of risk will work towards manage stressors and enhance protective factors. The control group will not receive any intervention, but they will fill out the same questionnaires as in the intervention group. The main result will be the incidence of new cases of anxiety disorders measured by CIDI, and the secondary results will be the reduction of anxiety (GAD-7) and depression (PHQ-9) symptoms, of the risk probability of anxiety and depression (predictA and predictD algorithms) and improvement of quality of life measured by SF-12 and EuroQol, and cost-effectiveness and cost-utility.

Interventions

BEHAVIORALprevANS intervention

prevANS intervention will be self-guided and can be implemented from the prevANS web or from the participants' Smartphone (through an APP). The prevANS intervention will have different intensities depending on the risk level of the population, evaluated from the already validated risk algorithm for anxiety: predictA. Participants will be classified as moderate-high or low risk of anxiety. Both groups of risk will receive information on their level and profile (risk factors) of anxiety and psychoeducational information periodically; also, they will work towards manage stressors and enhance protective factors. However, participants with moderate-high risk of anxiety will also receive a cognitive-behavioral training (problem solving, decision-making, handling thoughts / concerns and emotions and communicational skills).

Sponsors

Agencia Estatal de Investigación (AEI)
CollaboratorUNKNOWN
Institute of Health Carlos III (ISCIII)
CollaboratorUNKNOWN
Institute of Biomedical Research in Málaga (IBIMA)
CollaboratorUNKNOWN
European Regional Development Fund
CollaboratorOTHER
University of Malaga
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* GAD-7 \<10 at baseline * GAD-7 ≥10 at baseline and a negative diagnosis of anxiety disorders by CIDI

Exclusion criteria

* Not have a smartphone and internet for personal use * Unable to speak Spanish * Documented terminal illness * Documented cognitive impairment * Documented serious mental illness (psychosis, bipolar, addictions, etc.) * Being involved in any psychological intervention or treatment

Design outcomes

Primary

MeasureTime frameDescription
Primary Outcome Measure12 monthsRate of anxiety disorders measured by the Composite International Diagnostic Interview (CIDI). CIDI is a structured diagnostic interview that provides current diagnoses of anxiety disorders according to DSM.

Secondary

MeasureTime frameDescription
Depressive symptoms measured by the Patient Health Questionnaire-9 (PHQ-9)12 monthsThe Patient Health Questionnaire-9 (PHQ-9) measures symptoms of depression through 9 items, each of which is scored 0 ('not at all') to 3 ('nearly every day'). Low scores are equivalent to less symptoms of depression, the scalen range is 0 to 27 (9 items).
Probability of anxiety measured by the Spanish predictA risk algorithm12 monthsThe Spanish predictA risk algorithm measures 12 risk factors for anxiety disorders
Probability of depression measured by the Spanish predictD risk algorithm12 monthsThe Spanish predictD risk algorithm measures 13 risk factors for depression
Quality of life measured by SF-1212 monthsThe 12-item Short Form (SF-12) measures quality of life related to physical health and quality of life related to mental health. Scores on the scales range from 0 to 100. Higher scores are equivalent to better health-related quality of life.
Cost-effectiveness12 monthsIt will be conducted from two perspectives: (1) a societal perspective and (2) a National Health System perspective. We will calculate incremental cost-effectiveness ratio (ICER) using the incremental cost (difference in costs between arms) divided by incremental effectiveness (difference in the number of diagnoses of anxiety disorders between arms).
Cost-utility12 monthsIt will be conducted from two perspectives: (1) a societal perspective and (2) a National Health System perspective. We will calculate incremental cost-effectiveness ratio (ICER) using the incremental cost (difference in costs between arms) divided by incremental QALYs (difference in QALYs between arms). Quality-adjusted life years (QALYs) will be measured using the EuroQol five questionnaire (EuroQol-5D).
Acceptability and satisfaction with the intervention (prevANS intervention) measured by u-MARS scale12 monthsThe User Version of the Mobile Application Rating Scale (u-MARS) consists of 23 items assessing app quality, each of which is scored 1 ('poor') to 5('excellent'), except items 14-17 and item 19, which also include the not applicable option. Higher scores are equivalent to higher app quality.
Anxious symptoms measured by the General Anxiety Questionnaire (GAD-7)12 monthsThe General Anxiety Questionnaire (GAD-7) measures generalized anxiety disorder through 7 items, each of which is scored 0 ('not at all') to 3 ('nearly every day'). Low scores are equivalent to less symptoms of anxiety, the scale range is 0 to 21 (7 items).
Subgroup analysis according to age12 monthsA subgroup analysis will be conducted according to age of the participants (from 18 to 30 years; from 31 to 50 years; and \> 50 years)
Subgroup analysis according to sex12 monthsA subgroup analysis will be conducted according to sex of the participants (women or men)
Subgroup analysis according to education level12 monthsA subgroup analysis will be conducted according to education level of the participants (without primary education; primary education; secondary education; or higher education)
Subgroup analysis according to anxiety symptoms at baseline (through the GAD-7 questionnaire)12 monthsThe General Anxiety Questionnaire (GAD-7) measures generalized anxiety disorder through 7 items, each of which is scored 0 ('not at all') to 3 ('nearly every day'). Low scores are equivalent to less symptoms of anxiety, the scale range is 0 to 21 (7 items). The subgroups will be: 1) from 0 to 5 points; and 2) \> 5 points
Subgroup analysis according to depressive symptoms at baseline (through the PHQ-9 questionnaire)12 monthsThe Patient Health Questionnaire-9 (PHQ-9) measures symptoms of depression through 9 items, each of which is scored 0 ('not at all') to 3 ('nearly every day'). Low scores are equivalent to less symptoms of depression, the scalen range is 0 to 27 (9 items). The subgroups will be: 1) from 0 to 5 points; 2) from 6 to 10 points; and 3) \> 10 points
Subgroup analysis according to risk level of anxiety (through the predictA risk algorithm)12 monthsThe Spanish predictA risk algorithm measures 12 risk factors for anxiety disorders. The subgroups will be: 1) probability of risk from 0 to 6%; and 2) probability of risk \>6%
Subgroup analysis according to risk level of depression (through the predictD risk algorithm)12 monthsThe Spanish predictD risk algorithm measures 13 risk factors for depression. The subgroups will be: 1) probability of risk from 0 to 9%; and 2) probability of risk \>9%
Mediator of the intervention: cognitive change12 monthsThe cognitive change will be evaluated through the number of negative thoughts worked and modified in the app

Countries

Spain

Contacts

Primary ContactPatricia Moreno-Peral, PhD
predictmalaga@hotmail.com+34951030534
Backup ContactSonia Conejo-Cerón, PhD
soniafundacionimabis@hotmail.com+34951030534

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026